bluebird bio Inc BLUE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BLUE is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE
-
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm
-
BLUE INVESTOR NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
-
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm
-
Lost Money on bluebird bio, Inc.(BLUE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
-
BLUEBIRD BIO, INC. (NASDAQ: BLUE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE
Trading Information
- Previous Close Price
- $0.98
- Day Range
- $0.91–1.01
- 52-Week Range
- $0.88–5.52
- Bid/Ask
- $0.93 / $0.94
- Market Cap
- $180.21 Mil
- Volume/Avg
- 6.3 Mil / 8.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.53
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 323
- Website
- https://www.bluebirdbio.com
Comparables
Valuation
Metric
|
BLUE
|
FDMT
|
SWTX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.47 | 3.47 | 5.16 |
Price/Sales | 4.53 | 46.85 | 509.90 |
Price/Cash Flow | — | — | — |
Price/Earnings
BLUE
FDMT
SWTX
Financial Strength
Metric
|
BLUE
|
FDMT
|
SWTX
|
---|---|---|---|
Quick Ratio | 1.24 | 15.21 | 6.21 |
Current Ratio | 1.55 | 15.65 | 6.41 |
Interest Coverage | — | — | — |
Quick Ratio
BLUE
FDMT
SWTX
Profitability
Metric
|
BLUE
|
FDMT
|
SWTX
|
---|---|---|---|
Return on Assets (Normalized) | −12.29% | −25.94% | −39.61% |
Return on Equity (Normalized) | −30.63% | −28.64% | −45.43% |
Return on Invested Capital (Normalized) | −15.27% | −31.25% | −49.28% |
Return on Assets
BLUE
FDMT
SWTX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ybkkvmfdb | Yrmzw | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yzgdmytc | Zvddws | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yszbvcjf | Ncqzn | $99.6 Bil | |
MRNA
| Moderna Inc | Qfchrmrrh | Kxjk | $38.8 Bil | |
ARGX
| argenx SE ADR | Fxcrpdgjw | Flwv | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Ctcgmvsz | Xnkyc | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fqzjfxywj | Tbtwt | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mvbhppgds | Hyfss | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Syckjxtxb | Frkvm | $12.4 Bil | |
INCY
| Incyte Corp | Qdjpdxlf | Kpzbwrt | $11.9 Bil |